Photo taken from ESTRO/LinkedIn
Jul 25, 2024, 23:48
ESTRO – To Escalate or to De-Escalate Radiation Dose in Stage 3 NSCLC?
European Society for Radiotherapy and Oncology shared on LinkedIn:
“Key insights from ESTRO24 on the optimisation of radiation doses for stage III NSCLC in the era of immunotherapy and tyrosine kinase inhibitors. Learn about dose escalation trials, individualised treatment strategies, and the role of biomarkers in the guidance of therapy.”
Read further.
Source: European Society for Radiotherapy and Oncology/LinkedIn